×
About 1,918 results

ALLMedicine™ Mycobacterium Avium Complex Center

Research & Reviews  923 results

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung ...
https://doi.org/10.1007/s40261-021-01010-z 10.1093/cid/ciaa241 10.1093/infdis/jiaa354 10.1093/jac/dkn059 10.1007/s40265-019-01095-z 10.1128/JCM.01612-13 10.1128/CMR.05030-11 10.1371/journal.pone.0108703 10.1128/AAC.00700-16 10.1164/rccm.201807-1318OC 10.1007/s13318-020-00669-7 10.1164/rccm.201604-0700OC 10.1513/AnnalsATS.202008-925OC 10.1164/rccm.201704-0792LE
Clinical Drug Investigation; Hoy SM

Mar 16th, 2021 - Amikacin liposome inhalation suspension (ALIS) [Arikayce® Liposomal (EU); Arikayce® (USA)], a liposomal suspension of the aminoglycoside amikacin (590 mg) for nebulization via the Lamira® Nebulizer System, is available as add-on therapy for treatm...

In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, includi...
https://doi.org/10.1128/AAC.02611-20
Antimicrobial Agents and Chemotherapy; Kim DH, Kim SY et. al.

Mar 9th, 2021 - We evaluated the in vitro activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs aga...

A rare cause of secondary organising pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938981
BMJ Case Reports; Fernandes AL, Ferro A et. al.

Mar 6th, 2021 - Non-tuberculous mycobacterial pulmonary disease may have different clinical manifestations. We report a case of a 64-year-old woman presenting with persistent respiratory complaints, fever and radiological findings. Initially, she was diagnosed wi...

Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous m...
https://doi.org/10.1128/AAC.02131-20
Antimicrobial Agents and Chemotherapy; Schulthess B, Schäfle D et. al.

Feb 23rd, 2021 - Recent outbreaks of cardiac surgery-associated Mycobacterium chimaera infections have highlighted the importance of species differentiation within the Mycobacterium avium complex and pointed to a lack of antibiotic susceptibility data for M. chima...

Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium...
https://doi.org/10.1016/j.rmed.2021.106340
Respiratory Medicine; Han DW, Jo KW et. al.

Feb 22nd, 2021 - The temporal dynamics of cavity formation in patients with the noncavitary nodular bronchiectatic (NC-NB) form of Mycobacterium avium complex pulmonary disease (MAC-PD) have not yet been well described. We aimed to investigate the development of n...

see more →

Guidelines  1 results

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adul...
https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/0
Office of AIDS Research Advisory Council

May 28th, 2018 - Opportunistic infections (OIs) were the first clinical manifestations that alerted clinicians to the occurrence of the acquired immunodeficiency syndrome (AIDS). Pneumocystis pneumonia (PCP), toxoplasma encephalitis, cytomegalovirus (CMV) retiniti.

see more →

Drugs  11 results see all →

Clinicaltrials.gov  961 results

Mycobutin - rifabutin capsule-Pfizer Laboratories Div Pfizer Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e1a6613-bdd3-4261-93b3-d7f5cc09064b

Mar 24th, 2021 - MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung ...
https://doi.org/10.1007/s40261-021-01010-z 10.1093/cid/ciaa241 10.1093/infdis/jiaa354 10.1093/jac/dkn059 10.1007/s40265-019-01095-z 10.1128/JCM.01612-13 10.1128/CMR.05030-11 10.1371/journal.pone.0108703 10.1128/AAC.00700-16 10.1164/rccm.201807-1318OC 10.1007/s13318-020-00669-7 10.1164/rccm.201604-0700OC 10.1513/AnnalsATS.202008-925OC 10.1164/rccm.201704-0792LE
Clinical Drug Investigation; Hoy SM

Mar 16th, 2021 - Amikacin liposome inhalation suspension (ALIS) [Arikayce® Liposomal (EU); Arikayce® (USA)], a liposomal suspension of the aminoglycoside amikacin (590 mg) for nebulization via the Lamira® Nebulizer System, is available as add-on therapy for treatm...

In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, includi...
https://doi.org/10.1128/AAC.02611-20
Antimicrobial Agents and Chemotherapy; Kim DH, Kim SY et. al.

Mar 9th, 2021 - We evaluated the in vitro activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs aga...

A rare cause of secondary organising pneumonia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938981
BMJ Case Reports; Fernandes AL, Ferro A et. al.

Mar 6th, 2021 - Non-tuberculous mycobacterial pulmonary disease may have different clinical manifestations. We report a case of a 64-year-old woman presenting with persistent respiratory complaints, fever and radiological findings. Initially, she was diagnosed wi...

Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous m...
https://doi.org/10.1128/AAC.02131-20
Antimicrobial Agents and Chemotherapy; Schulthess B, Schäfle D et. al.

Feb 23rd, 2021 - Recent outbreaks of cardiac surgery-associated Mycobacterium chimaera infections have highlighted the importance of species differentiation within the Mycobacterium avium complex and pointed to a lack of antibiotic susceptibility data for M. chima...

see more →

News  21 results

Papulonecrotic Tuberculid Secondary to Mycobacterium avium Complex
https://www.mdedge.com/dermatology/article/212703/infectious-diseases/papulonecrotic-tuberculid-secondary-mycobacterium?channel=44
Brittany Urso, MD, Corey Georgesen, MD et. al.

Nov 20th, 2019 - To the Editor: Papulonecrotic tuberculid (PNT) is a cutaneous hypersensitivity reaction to antigenic components of Mycobacterium species, most commonly Mycobacterium tuberculosis. According to a PubMed search of articles indexed for MEDLINE using.

FDA approves Arikayce for MAC lung diseases
https://www.mdedge.com/pulmonary-health-hub/article/176296/pulmonology/fda-approves-arikayce-mac-lung-diseases
Christopher Palmer

Oct 3rd, 2018 - The Food and Drug Administration has approved an amikacin liposome inhalation suspension (Arikayce) for the treatment of lung disease that has been caused by members of the Mycobacterium avium complex and is refractory to other treatments. In a ra.

FDA Clears Antibacterial Arikayce for MAC Lung Disease
https://www.staging.medscape.com/viewarticle/902764

Sep 30th, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...

FDA Clears Antibacterial Arikayce for MAC Lung Disease
https://www.medscape.com/viewarticle/902764

Sep 30th, 2018 - The US Food and Drug Administration (FDA) has approved amikacin liposome inhalation suspension (Arikayce, Insmed) for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited or no alternative treatment options. Arika...

FDA Approves Inhaled Amikacin for Non-TB Lung Infection
https://www.medpagetoday.com/pulmonology/generalpulmonary/75407

Sep 28th, 2018 - WASHINGTON -- The FDA approved Insmed's amikacin liposome inhalation suspension (Arikayce) for a limited population of patients with a certain type of non-tuberculosis mycobacterial lung infection, the agency said today. In what was described as t...

see more →

Patient Education  1 results see all →